share_log

Altamira Therapeutics | F-3: Registration statement for specified transactions by certain foreign private issuers

SEC announcement ·  Jan 8 00:00
Summary by Moomoo AI
Altamira Therapeutics Ltd., a biopharmaceutical company, filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on January 8, 2024. The Bermuda-based company, led by President Thomas Meyer, PhD, is preparing for the proposed sale of common shares to the public, which will commence as soon as practicable after the registration statement becomes effective. The registration includes 162,548 common shares, which may be acquired upon the exercise of certain warrants issued in connection with a Warrant Inducement Agreement dated December 7, 2023. These warrants were issued to the holder on May 1, 2023, and additional warrants were provided on December 15, 2023, as an inducement for early exercise. The initial exercise price for the new warrants is set at CHF 6.656. Altamira Therapeutics will not receive...Show More
Altamira Therapeutics Ltd., a biopharmaceutical company, filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on January 8, 2024. The Bermuda-based company, led by President Thomas Meyer, PhD, is preparing for the proposed sale of common shares to the public, which will commence as soon as practicable after the registration statement becomes effective. The registration includes 162,548 common shares, which may be acquired upon the exercise of certain warrants issued in connection with a Warrant Inducement Agreement dated December 7, 2023. These warrants were issued to the holder on May 1, 2023, and additional warrants were provided on December 15, 2023, as an inducement for early exercise. The initial exercise price for the new warrants is set at CHF 6.656. Altamira Therapeutics will not receive any proceeds from the sale of shares by the selling shareholders, who will cover any underwriting discounts and commissions. The common shares are traded on the NASDAQ under the symbol 'CYTO', with the closing price on January 5, 2024, being $3.12 per share. The company has undergone several corporate actions, including reverse share splits and a change in the currency denomination of its authorized share capital.

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Doc 4

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more